Find policies, billing codes, payers, states, and providers
HCPCS J9309: Polatuzumab Vedotin Injection, 1 mg
HCPCS Level II code J9309 designates polatuzumab vedotin-piiq billed per 1 mg and is used for administration of this injectable oncology therapy. This code matters nationally as polatuzumab vedotin is an advanced targeted agent for certain hematologic malignancies; accurate coding affects clinical documentation, reimbursement, and access to therapy across care settings. Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find a concise overview of what J9309 represents, typical sites of service, and the clinical context for billing an injectable oncology agent. The publication summarizes payer coverage considerations and common billing modifiers used with this HCPCS code. It also provides benchmarking guidance for service lines that bill oncology injections, highlights relevant policy updates affecting HCPCS drug billing, and outlines administrative details clinics and hospitals commonly track when managing high-cost infused therapies. Data not available in the input is noted where appropriate.
Customize your policy alerts
Sign up for hcpcs J9309 policy alerts
Get alerted when payer policies referencing J9309 are released or updated.
Monitor payer policy activity
Billing Code Overview
HCPCS Level II code J9309 represents the drug product polatuzumab vedotin-piiq, billed per 1 mg of the drug. This code is used for administration of the medication itself; the service type is injectable chemotherapy or targeted oncology therapy. The typical site of service for claims using J9309 is hospital outpatient departments, physician offices, or infusion centers where intravenous or injectable cancer therapies are administered.
Data not available in the input.